Why the study?
Does vericiguat reduce pulmonary vein arrhythmogenesis in heart failure models?
Population
Isolated pulmonary vein myocytes and heart failure rabbits
Comparison
Vericiguat vs Control or pretreated with PKG inhibitor KT5823…
Design
Preclinical
Follow-up
4 weeks (in vivo)
Key result
Vericiguat significantly reduced pulmonary vein spontaneous activity and diastolic tension in heart failure models, attenuating arrhythmogenesis through PKG- and PKA-dependent mechanisms.
Authors
Loading...
May support vericiguat's antiarrhythmic potential in HF; hypothesis-generating and requires clinical validation.
Does vericiguat reduce pulmonary vein arrhythmogenesis in heart failure models?
Vericiguat attenuates pulmonary vein arrhythmogenesis in heart failure models through PKG- and PKA-dependent mechanisms, providing a potential mechanistic basis for antiarrhythmic benefits in HF.
Chan et al. (2026) studied Heart failure and atrial fibrillation. Vericiguat vs. Without vericiguat was evaluated on Pulmonary vein spontaneous activity, diastolic tension, and electrical activity. Vericiguat significantly reduced pulmonary vein spontaneous activity and diastolic tension in heart failure models, attenuating arrhythmogenesis through PKG- and PKA-dependent mechanisms.